BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27847820)

  • 21. Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line SCA3.A11.
    Hansen SK; Borland H; Hasholt LF; Tümer Z; Nielsen JE; Rasmussen MA; Nielsen TT; Stummann TC; Fog K; Hyttel P
    Stem Cell Res; 2016 May; 16(3):553-6. PubMed ID: 27346190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
    Paulino R; Nóbrega C
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of two induced pluripotent stem cell lines, GZHMCi009-A and GZHMCi010-A, derived from peripheral blood mononuclear cells of two SCA3 patients with 14/74 CAG repeats of the ATXN3 mutation.
    Yinghong Y; Qian L; Bing S; Yingjun X; Wenzhi H; Bangzhu C; Xiaofang S
    Stem Cell Res; 2022 May; 61():102782. PubMed ID: 35421843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Excitotoxic Effects of N-Butylidenephthalide Revealed by Chemically Insulted Purkinje Progenitor Cells Derived from SCA3 iPSCs.
    Yang HH; Chiang IT; Liu JW; Hsieh J; Lee JH; Lu HE; Tso HS; Deng YC; Kao JC; Wu JR; Harn HJ; Chiou TW
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
    Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
    Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
    Chen ZS; Huang X; Talbot K; Chan HYE
    Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis.
    Nóbrega C; Simões AT; Duarte-Neves J; Duarte S; Vasconcelos-Ferreira A; Cunha-Santos J; Pereira D; Santana M; Cavadas C; de Almeida LP
    Adv Exp Med Biol; 2018; 1049():349-367. PubMed ID: 29427113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcription factor EB-mediated mesenchymal stem cell therapy induces autophagy and alleviates spinocerebellar ataxia type 3 defects in neuronal cells model.
    Han X; de Dieu Habimana J; Li AL; Huang R; Mukama O; Deng W; Wang L; Zhang Y; Wang W; Deng S; Peng K; Ni B; Zhang S; Huang J; Yan XX; Li Z
    Cell Death Dis; 2022 Jul; 13(7):622. PubMed ID: 35851059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
    He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
    Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing.
    McIntosh CS; Aung-Htut MT; Fletcher S; Wilton SD
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment.
    Onofre I; Mendonça N; Lopes S; Nobre R; de Melo JB; Carreira IM; Januário C; Gonçalves AF; de Almeida LP
    Sci Rep; 2016 Jun; 6():28220. PubMed ID: 27328712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.
    Schuster KH; Zalon AJ; DiFranco DM; Putka AF; Stec NR; Jarrah SI; Naeem A; Haque Z; Zhang H; Guan Y; McLoughlin HS
    Mol Ther; 2024 May; 32(5):1359-1372. PubMed ID: 38429929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alteration of methylation status in the ATXN3 gene promoter region is linked to the SCA3/MJD.
    Wang C; Peng H; Li J; Ding D; Chen Z; Long Z; Peng Y; Zhou X; Ye W; Li K; Xu Q; Ai S; Song C; Weng L; Qiu R; Xia K; Tang B; Jiang H
    Neurobiol Aging; 2017 May; 53():192.e5-192.e10. PubMed ID: 28094059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
    Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
    J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population genetics and new insight into range of CAG repeats of spinocerebellar ataxia type 3 in the Han Chinese population.
    Gan SR; Ni W; Dong Y; Wang N; Wu ZY
    PLoS One; 2015; 10(8):e0134405. PubMed ID: 26266536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
    Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
    Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
    Da Silva JD; Teixeira-Castro A; Maciel P
    Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
    Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.